S
Suresh H. Advani
Researcher at Jaslok Hospital
Publications - 399
Citations - 4732
Suresh H. Advani is an academic researcher from Jaslok Hospital. The author has contributed to research in topics: Myeloid leukemia & Leukemia. The author has an hindex of 32, co-authored 397 publications receiving 4543 citations. Previous affiliations of Suresh H. Advani include Memorial Hospital of South Bend & National Institutes of Health.
Papers
More filters
Journal ArticleDOI
The spectrum of molecular alterations in the evolution of chronic myelocytic leukemia.
HG Ahuja,Menashe Bar-Eli,Zalmen A. Arlin,Suresh H. Advani,Steven L. Allen,John M. Goldman,David S. Snyder,A Foti,Martin J. Cline +8 more
TL;DR: It is concluded that heterogeneous alterations in the p53 gene and occasionally in the N-RAS genes accompany the evolution of chronic phase CML to blast crisis.
Journal ArticleDOI
Intravenous aflibercept for treatment of recurrent symptomatic malignant ascites in patients with advanced ovarian cancer: a phase 2, randomised, double-blind, placebo-controlled study.
Walter H. Gotlieb,Frédéric Amant,Suresh H. Advani,Chanchal Goswami,Hal W. Hirte,Diane Provencher,Naresh Somani,S. Diane Yamada,Jean-Francois Tamby,Ignace Vergote +9 more
TL;DR: In this paper, the authors present the final results of a multicentre study of the efficacy and safety of aflibercept, a potent inhibitor of both VEGF and placental growth factor, in the treatment of malignant ascites.
Journal ArticleDOI
Treatment of acute lymphoblastic leukaemia in countries with limited resources; lessons from use of a single protocol in India over a twenty year peroid
I. Magrath,Viswanathan Shanta,Suresh H. Advani,M. Adde,Laxman Singh Arya,S D Banavali,Manorama Bhargava,K. Bhatia,Martin Gutierrez,D. Liewehr,Suresh K. Pai,T.G. Sagar,David Venzon +12 more
TL;DR: Comparison of patient characteristics with published series from Western nations indicated that patients from all three Indian centres had more extensive disease at presentation, as measured by WBC, lymphadenopathy and organomegaly, and these findings have important implications for the treatment of ALL in countries of low socioeconomic status.
Journal ArticleDOI
First-line gemcitabine versus epirubicin in postmenopausal women aged 60 or older with metastatic breast cancer: a multicenter, randomized, phase III study
O. Feher,P. Vodvarka,Jacek Jassem,G. Morack,Suresh H. Advani,K. S. Khoo,D. C. Doval,S. Ermisch,Debasish Roychowdhury,M. A. Miller,G. von Minckwitz +10 more
TL;DR: In this study, epirubicin was superior to gemcitabine in the treatment of MBC in women age > or =60, confirming that anthracyclines remain important drugs for first-line treatment ofMBC.
Journal ArticleDOI
Acute lymphoblastic leukemia in India: An analysis of prognostic factors using a single treatment regimen
Suresh H. Advani,Suresh K. Pai,David Venzon,Melissa Adde,P. K. Kurkure,Chandrika N. Nair,Bhawna Sirohi,S D Banavali,R. Hawaldar,B. B. Kolhatkar,T. Vats,Ian Magrath +11 more
TL;DR: Age and WBC alone inadequately defined risk groups, suggesting that prognostic factors may vary in different world regions, and the CR and EFS rates achieved represent a significant improvement over previous results at this institution.